Clinical Trial Update: MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial of anti-MAGE-A3/12 TCR-gene engineered lymphocytes in metastatic cancers was terminated. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Melanoma
• Renal Cancer

Drugs mentioned

• MAGE-A3/12 TCR-gene engineered lymphocytes

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Cancer, Metastatic Renal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2013-03-27